Table 1.
Baseline demographics and management for all patients according to sex
| All (n = 7878) | Men (n = 4717) | Women (n = 3161) | P-value | |
|---|---|---|---|---|
| Age (years), mean ± SD | 66.3 ± 13.7 | 64.0 ± 13.0 | 69.7 ± 13.9 | <0.001 |
| SIMD quintile, n (%) | <0.001 | |||
| 1 (most deprived) | 3265 (41.5) | 1865 (39.5) | 1400 (44.3) | 0.002a |
| 2 | 1418 (18.0) | 833 (17.7) | 585 (18.5) | |
| 3 | 1126 (14.3) | 720 (15.3) | 406 (12.8) | |
| 4 | 993 (12.6) | 623 (13.2) | 370 (11.7) | |
| 5 | 1074 (13.6) | 675 (14.3) | 399 (12.6) | |
| Diagnosis, n (%) | <0.001 | |||
| STEMI | 2042 (25.9) | 1399 (29.7) | 643 (20.3) | |
| NSTEMI | 3957 (50.2) | 2322 (49.2) | 1635 (51.7) | |
| HA | 1425 (18.1) | 749 (15.9) | 676 (21.4) | |
| Unspecified MI | 454 (5.8) | 247 (5.2) | 207 (6.5) | |
| Comorbidities, n (%) | ||||
| Hypertension | 1920 (24.4) | 986 (20.9) | 934 (29.5) | <0.001 |
| Diabetes | 1172 (14.9) | 672 (14.2) | 500 (15.8) | 0.055 |
| Atrial fibrillation | 822 (10.4) | 431 (9.1) | 391 (12.4) | <0.001 |
| Renal failure | 836 (10.6) | 416 (8.8) | 420 (13.3) | <0.001 |
| Respiratory disease | 1186 (15.1) | 579 (12.3) | 607 (19.2) | <0.001 |
| Cerebrovascular disease | 511 (6.5) | 253 (5.4) | 258 (8.2) | <0.001 |
| Peripheral vascular disease | 572 (7.3) | 340 (7.2) | 232 (7.3) | 0.826 |
| Heart failure | 794 (10.1) | 442 (9.4) | 352 (11.1) | 0.012 |
| Previous myocardial infarction | 1571 (19.9) | 967 (20.5) | 604 (19.1) | 0.130 |
| Dementia | 152 (1.9) | 63 (1.3) | 89 (2.8) | <0.001 |
| Depression | 165 (2.1) | 68 (1.4) | 97 (3.1) | <0.001 |
| Charlson score | <0.001 | |||
| 0 | 4322 (54.9) | 2701 (57.3) | 1621 (51.3) | |
| 1–3 | 2979 (37.8) | 1708 (36.2) | 1271 (40.2) | |
| ≥4 | 577 (7.3) | 308 (6.5) | 269 (8.5) | |
| Pre-admission medical therapy, n (%) | ||||
| Anticoagulant | ||||
| Warfarin | 340 (4.3) | 175 (3.7) | 165 (5.2) | 0.001 |
| Any anticoagulant | 463 (5.9) | 239 (4.9) | 224 (7.1) | <0.001 |
| Antiplatelet | ||||
| Aspirin | 2595 (32.9) | 1524 (32.3) | 1071 (33.9) | 0.145 |
| Clopidogrel | 743 (9.4) | 381 (8.1) | 362 (11.5) | <0.001 |
| Ticagrelor | 110 (1.5) | 66 (1.4) | 52 (1.6) | 0.379 |
| Any antiplatelet | 3134 (39.8) | 1792 (38.0) | 1342 (42.5) | <0.001 |
| Dual antiplatelet | 312 (4.0) | 173 (3.7) | 139 (4.4) | 0.104 |
| Statin | 3523 (44.7) | 2040 (43.2) | 1483 (46.9) | 0.001 |
| Beta-blocker | 2542 (32.3) | 1440 (30.5) | 1102 (34.9) | <0.001 |
| ACE inhibitor or ARB | 2739 (34.8) | 1612 (34.2) | 1127 (35.7) | 0.177 |
| Mineralocorticoid receptor antagonist | 145 (1.8) | 86 (1.8) | 59 (1.9) | 0.889 |
| Combined therapy | ||||
| Anticoagulant or antiplatelet | 3517 (44.6) | 1984 (42.1) | 1533 (48.5) | <0.001 |
| Anticoagulant or dual antiplatelet | 770 (9.8) | 407 (8.6) | 363 (11.5) | <0.001 |
| Anticoagulant or anticoagulant + antiplatelet | 463 (5.9) | 239 (5.1) | 224 (7.1) | <0.001 |
| Anticoagulant or anticoagulant + dual antiplatelet | 463 (5.9) | 239 (5.1) | 224 (7.1) | <0.001 |
| ≥3 medications | 2488 (31.6) | 1483 (31.4) | 1005 (31.8) | 0.740 |
| Type of admission, n (%) | ||||
| Emergency to invasive centre | 1473 (18.7) | 1035 (21.9) | 438 (13.9) | <0.001 |
| Non-emergency to invasive centre | 997 (12.7) | 636 (13.5) | 361 (11.4) | 0.007 |
| Emergency to local hospital | 4986 (63.3) | 2783 (59.0) | 2203 (69.7) | <0.001 |
| Non-emergency to local hospital | 422 (5.4) | 263 (5.6) | 159 (5.0) | 0.292 |
| Coronary angiography, n (%) | ||||
| All | 4866 (61.8) | 3219 (68.2) | 1647 (52.1) | <0.001 |
| PCI | 3149 (40.0) | 2192 (46.5) | 957 (30.3) | <0.001 |
| 64.7b | 68.1b | 58.1b | <0.001 | |
| Length of stay (days), median (IQR) | 4 (2–7) | 4 (2–7) | 5 (2–8) | <0.001 |
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HA, hospitalized angina; IQR, interquartile range; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; SIMD, Scottish Index of Multiple Deprivation; STEMI, ST-elevation myocardial infarction.
a
P-value for SIMD Q1–Q3 vs Q4–Q5.
b
Those who had PCI as a proportion of those who underwent coronary angiography.